S&P 500   3,923.68 (-4.04%)
DOW   31,490.07 (-3.57%)
QQQ   291.14 (-4.91%)
AAPL   140.82 (-5.64%)
MSFT   254.08 (-4.77%)
FB   192.24 (-5.12%)
GOOGL   2,237.99 (-3.93%)
AMZN   2,142.25 (-7.16%)
TSLA   709.81 (-6.80%)
NVDA   169.38 (-6.82%)
BABA   87.31 (-5.09%)
NIO   15.83 (-4.81%)
AMD   96.28 (-6.04%)
CGC   5.59 (-5.09%)
MU   71.05 (-4.61%)
T   20.23 (-1.65%)
GE   75.20 (-1.57%)
F   12.78 (-5.54%)
DIS   104.30 (-3.99%)
AMC   12.76 (-1.09%)
PFE   50.40 (-1.83%)
PYPL   77.18 (-3.22%)
NFLX   177.19 (-7.02%)
S&P 500   3,923.68 (-4.04%)
DOW   31,490.07 (-3.57%)
QQQ   291.14 (-4.91%)
AAPL   140.82 (-5.64%)
MSFT   254.08 (-4.77%)
FB   192.24 (-5.12%)
GOOGL   2,237.99 (-3.93%)
AMZN   2,142.25 (-7.16%)
TSLA   709.81 (-6.80%)
NVDA   169.38 (-6.82%)
BABA   87.31 (-5.09%)
NIO   15.83 (-4.81%)
AMD   96.28 (-6.04%)
CGC   5.59 (-5.09%)
MU   71.05 (-4.61%)
T   20.23 (-1.65%)
GE   75.20 (-1.57%)
F   12.78 (-5.54%)
DIS   104.30 (-3.99%)
AMC   12.76 (-1.09%)
PFE   50.40 (-1.83%)
PYPL   77.18 (-3.22%)
NFLX   177.19 (-7.02%)
S&P 500   3,923.68 (-4.04%)
DOW   31,490.07 (-3.57%)
QQQ   291.14 (-4.91%)
AAPL   140.82 (-5.64%)
MSFT   254.08 (-4.77%)
FB   192.24 (-5.12%)
GOOGL   2,237.99 (-3.93%)
AMZN   2,142.25 (-7.16%)
TSLA   709.81 (-6.80%)
NVDA   169.38 (-6.82%)
BABA   87.31 (-5.09%)
NIO   15.83 (-4.81%)
AMD   96.28 (-6.04%)
CGC   5.59 (-5.09%)
MU   71.05 (-4.61%)
T   20.23 (-1.65%)
GE   75.20 (-1.57%)
F   12.78 (-5.54%)
DIS   104.30 (-3.99%)
AMC   12.76 (-1.09%)
PFE   50.40 (-1.83%)
PYPL   77.18 (-3.22%)
NFLX   177.19 (-7.02%)
S&P 500   3,923.68 (-4.04%)
DOW   31,490.07 (-3.57%)
QQQ   291.14 (-4.91%)
AAPL   140.82 (-5.64%)
MSFT   254.08 (-4.77%)
FB   192.24 (-5.12%)
GOOGL   2,237.99 (-3.93%)
AMZN   2,142.25 (-7.16%)
TSLA   709.81 (-6.80%)
NVDA   169.38 (-6.82%)
BABA   87.31 (-5.09%)
NIO   15.83 (-4.81%)
AMD   96.28 (-6.04%)
CGC   5.59 (-5.09%)
MU   71.05 (-4.61%)
T   20.23 (-1.65%)
GE   75.20 (-1.57%)
F   12.78 (-5.54%)
DIS   104.30 (-3.99%)
AMC   12.76 (-1.09%)
PFE   50.40 (-1.83%)
PYPL   77.18 (-3.22%)
NFLX   177.19 (-7.02%)
NASDAQ:GALT

Galectin Therapeutics Insider Trades

$1.28
-0.07 (-5.19%)
(As of 05/18/2022 04:00 PM ET)
Add
Compare
Today's Range
$1.28
$1.39
50-Day Range
$1.26
$1.86
52-Week Range
$1.26
$4.45
Volume
64,835 shs
Average Volume
113,585 shs
Market Capitalization
$75.96 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
1.64

Galectin Therapeutics (NASDAQ:GALT) Insider Buying and Selling Activity

Current
Insider Ownership
Percentage
39.40%
Number Of
Insiders Buying
(Last 12 Months)
3
Amount Of
Insider Buying
(Last 12 Months)
$84.62 K
Number Of
Insiders Selling
(Last 12 Months)
1
Amount Of
Insider Selling
(Last 12 Months)
$274.50 K

Insider Buying and Selling by Quarter

Get GALT Insider Trade Alerts

Want to know when executives and insiders are buying or selling Galectin Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily.


Galectin Therapeutics (NASDAQ:GALT) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
4/18/2022Kevin D FreemanDirectorBuy5,000$1.71$8,550.0060,000  
4/4/2022Richard A Jr. ZordaniDirectorBuy5,000$1.60$8,000.0024,583  
2/2/2022Fund L.P. 10XMajor ShareholderSell10,000$2.10$21,000.00  
1/21/2022Elissa J SchwartzDirectorBuy1,000$2.00$2,000.00  
1/19/2022Kevin D FreemanDirectorBuy5,000$1.96$9,800.00  
1/14/2022Richard A Jr. ZordaniDirectorBuy5,000$2.02$10,100.00  
1/11/2022Fund L.P. 10XMajor ShareholderSell10,000$2.10$21,000.00  
12/6/2021Kevin D FreemanDirectorBuy5,000$2.34$11,700.00  
12/2/2021Fund L.P. 10XMajor ShareholderSell10,000$2.37$23,700.00  
11/1/2021Fund L.P. 10XMajor ShareholderSell10,000$3.19$31,900.00  
10/29/2021Kevin D FreemanDirectorBuy2,000$3.17$6,340.00  
10/21/2021Kevin D FreemanDirectorBuy2,000$3.19$6,380.00  
10/19/2021Kevin D FreemanDirectorBuy3,000$3.37$10,110.00  
10/15/2021Fund L.P. 10XMajor ShareholderSell10,000$3.37$33,700.00  
10/4/2021Fund L.P. 10XMajor ShareholderSell10,000$3.62$36,200.00  
9/23/2021Kevin D FreemanDirectorBuy3,000$3.88$11,640.00  
9/1/2021Fund L.P. 10XMajor ShareholderSell10,000$3.91$39,100.00  
8/2/2021Fund L.P. 10XMajor ShareholderSell10,000$3.25$32,500.00  
7/9/2021Fund L.P. 10XMajor ShareholderSell10,000$3.54$35,400.00  
5/3/2021Fund L.P. 10XMajor ShareholderSell27,500$3.97$109,175.00
4/5/2021Kevin D FreemanDirectorBuy5,000$2.04$10,200.0023,469  
4/1/2021Fund L.P. 10XMajor ShareholderSell10,000$2.16$21,600.00  
2/2/2021Fund L.P. 10XMajor ShareholderSell10,000$2.04$20,400.00  
1/11/2021Gilbert F AmelioDirectorSell60,000$2.17$130,200.0060,614  
10/13/2020Fund L.P. 10XMajor ShareholderSell10,000$2.97$29,700.00  
9/4/2020Kevin D FreemanDirectorBuy5,000$2.57$12,850.0023,469  
3/19/2020Kevin D FreemanDirectorBuy6,000$1.69$10,140.00
1/17/2020Fund L.P. 10XMajor ShareholderSell10,000$2.97$29,700.00  
11/15/2019Kevin D FreemanDirectorBuy3,000$3.36$10,080.0023,469  
10/10/2019Fund L.P. 10XMajor ShareholderSell17,000$3.73$63,410.00  
9/6/2019Kevin D FreemanDirectorBuy1,290$3.71$4,785.9023,469  
5/31/2019Jack W CallicuttCFOBuy2,354$4.28$10,075.123,614  
5/31/2019Richard E UihleinDirectorBuy4,680,606$4.28$20,032,993.683,128,489  
4/9/2019Richard E UihleinDirectorBuy20,700$4.82$99,774.002,628,489  
4/5/2019Kevin D FreemanDirectorBuy500$4.73$2,365.0022,043  
2/22/2019Marc RubinDirectorSell51,185$6.02$308,133.7013,581  
2/8/2019Kevin D FreemanDirectorBuy1,500$4.29$6,435.0022,043  
1/31/2019Gilbert F AmelioDirectorSell30,000$5.00$150,000.00  
1/29/2019Richard E UihleinDirectorBuy51,500$4.87$250,805.002,538,289  
9/25/2018Kary EldredDirectorBuy2,000$6.10$12,200.0041,382  
9/10/2018Gilbert S OmennDirectorSell19,370$6.02$116,607.4056,561  
9/7/2018Gilbert S OmennDirectorSell11,000$6.03$66,330.0056,561  
9/4/2018Marc RubinDirectorSell11,900$6.58$78,302.00  
8/30/2018Marc RubinDirectorSell58,100$6.08$353,248.0084,581  
6/25/2018Joel LewisDirectorBuy1,000$7.06$7,060.0051,480  
6/20/2018Jack W CallicuttCFOSell226,000$8.61$1,945,860.00103,993  
6/18/2018Fund L.P. 10XMajor ShareholderSell151,860$8.61$1,307,514.60  
6/18/2018James C CzirrDirectorSell60,000$9.06$543,600.00  
6/15/2018James C CzirrDirectorSell15,475$8.47$131,073.25  
6/14/2018Fund L.P. 10XMajor ShareholderSell76,385$8.28$632,467.80  
6/13/2018Harold H ShlevinCOOSell43,698$7.41$323,802.18  
6/13/2018James C CzirrDirectorSell208,140$7.17$1,492,363.80  
6/13/2018Peter G TraberCEOSell100,000$7.51$751,000.00207,333  
6/11/2018Harold H ShlevinCOOSell115,054$5.84$671,915.36103,914  
6/11/2018Jack W CallicuttCFOSell120,000$5.85$702,000.00101,260  
6/8/2018Jack W CallicuttCFOSell100,000$5.75$575,000.00101,260  
6/8/2018James C CzirrDirectorSell110,000$5.88$646,800.00  
6/8/2018Peter G TraberCEOSell70,000$5.86$410,200.00177,333  
6/7/2018Harold H ShlevinCOOSell109,969$5.20$571,838.8058,094  
6/5/2018Harold H ShlevinCOOSell20,831$5.15$107,279.6559,414  
6/4/2018Fund L.P. 10XMajor ShareholderSell50,000$5.12$256,000.00  
6/1/2018Harold H ShlevinCOOSell119,200$5.06$603,152.00103,914  
5/31/2018Jack W CallicuttCFOSell46,651$5.00$233,255.0047,911  
4/16/2018Theodore Daniel ZucconiDirectorSell4,000$3.58$14,320.005,083  
4/4/2018Jack W CallicuttCFOSell3,349$5.00$16,745.004,609  
2/1/2018Kevin D FreemanDirectorBuy2,000$4.10$8,200.0022,043  
1/26/2018Fund L.P. 10XMajor ShareholderSell244,444$5.43$1,327,330.92  
1/25/2018James C CzirrDirectorSell205,144$5.45$1,118,034.80  
12/8/2017Marc RubinDirectorBuy7,000$1.85$12,950.0055,581  
5/23/2017Theodore Daniel ZucconiDirectorBuy1,000$2.27$2,270.001,083  
1/5/2016Arthur GreenbergDirectorBuy1,666$1.72$2,865.52109,445  
8/12/2015Peter G TraberCEOBuy2,000$2.00$4,000.00  
6/1/2015Kevin D FreemanDirectorBuy2,083$2.70$5,624.10  
6/1/2015Peter G TraberCEOBuy4,000$2.53$10,120.00  
8/19/2014Arthur GreenbergDirectorBuy1,000$4.56$4,560.00  
8/15/2014Kevin D FreemanDirectorBuy1,000$4.70$4,700.00  
8/14/2014Jack W CallicuttCFOBuy1,000$4.55$4,550.00  
8/14/2014Peter G TraberCEOBuy4,000$4.46$17,840.00  
8/13/2014Peter G TraberCEOBuy1,000$4.42$4,420.00  
4/11/2014Steven PrelackDirectorSell6,000$11.84$71,040.00  
1/13/2014James C CzirrChairmanSell100,000$14.84$1,484,000.00  
12/4/2013Marc RubinDirectorBuy3,000$8.69$26,070.00  
11/19/2013Arthur GreenbergDirectorBuy2,000$6.55$13,100.00  
11/19/2013Peter G TraberCEOBuy1,000$5.53$5,530.00  
11/18/2013Peter G TraberCEOBuy1,000$5.80$5,800.00  
11/15/2013James C CzirrChairmanBuy1,000$6.90$6,900.00  
6/3/2013John F MauldinDirectorBuy1,176$4.21$4,950.96  
5/28/2013Kevin D FreemanDirectorBuy1,000$4.21$4,210.00  
10/12/2012Peter G TraberCEOBuy2,500$2.11$5,275.00  
10/9/2012Peter G TraberCEOBuy2,500$2.00$5,000.00  
10/8/2012Peter G TraberCEOBuy5,000$2.07$10,350.00  
(Data available from 1/1/2013 forward)












Galectin Therapeutics (NASDAQ:GALT) Insider Trade Frequently Asked Questions

Who is on Galectin Therapeutics's Insider Roster?

The list of insiders at Galectin Therapeutics includes Elissa J Schwartz, Fund L.P. 10X, Gilbert F Amelio, Jack W Callicutt, Kevin D Freeman, Richard A Jr. Zordani, and Richard E Uihlein. Learn more on insiders at GALT.

What percentage of Galectin Therapeutics stock is owned by insiders?

39.40% of Galectin Therapeutics stock is owned by insiders. Learn more on GALT's insider holdings.

Which Galectin Therapeutics insiders have been buying company stock?

The following insiders have purchased Galectin Therapeutics stock in the last 24 months: Elissa J Schwartz ($2,000.00), Kevin D Freeman ($87,570.00), and Richard A Jr. Zordani ($18,100.00).

How much insider buying is happening at Galectin Therapeutics?

Insiders have purchased a total of 46,000 Galectin Therapeutics shares in the last 24 months for a total of $107,670.00 bought.

Which Galectin Therapeutics insiders have been selling company stock?

The following insiders have sold Galectin Therapeutics stock in the last 24 months: Fund L.P. 10X ($455,375.00), and Gilbert F Amelio ($130,200.00).

How much insider selling is happening at Galectin Therapeutics?

Insiders have sold a total of 207,500 Galectin Therapeutics shares in the last 24 months for a total of $585,575.00 sold.

This page was last updated on 5/18/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.